open access

Vol 59, No 3 (2008)
Original papers
Published online: 2008-05-08
Submitted: 2013-02-15
Get Citation

The polymorphism in insulin receptor substrate-1 gene and birth weight in neonates at term

Edyta Simońska-Cichocka, Janusz Gumprecht, Marcin Zychma, Agnieszka Witkowska, Hanna Misiołek, Helena Slawska, Anna Oslislo, Władysław Grzeszczak
Endokrynologia Polska 2008;59(3):212-216.

open access

Vol 59, No 3 (2008)
Original papers
Published online: 2008-05-08
Submitted: 2013-02-15

Abstract

Background: The mutation of the IRS-1 gene is one of the genetic risk factors which, it is speculated, is associated with insulin resistance or predisposition to type 2 diabetes. The aim of our study was to evaluate the association between the Gly972Arg polymorphism in the IRS-1 gene and birth weight in newborn children with adequate gestational age.
Material and methods: 100 newborn children with adequate gestational age (38–42 weeks), whose mother had no disorders during pregnancy, were studied. Genomic DNA was extracted from umbilical cord blood leukocytes, and Gly972Arg polymorphism in the IRS-1 gene was genotyped using the PCR-based method.
Results: Birth weight was significantly lower in the newborn with the IRS-1 Gly972Arg polymorphism compared with a control group (3161.75 ± 380.86 g vs. 3427.92 ± 468.86 g). Body length and head circumference at birth were also lower in the neonates with that polymorphism (54.38 ± 3.13 cm vs. 52.69 ± 2.91 cm, and 34.08 ± 1.47 vs. 33.63 ± 0.81, respectively).
Conclusions: The results suggest that the Gly972Arg genotype is associated with lower birth weight, body length and head circumference in neonates with adequate gestational age.

Abstract

Background: The mutation of the IRS-1 gene is one of the genetic risk factors which, it is speculated, is associated with insulin resistance or predisposition to type 2 diabetes. The aim of our study was to evaluate the association between the Gly972Arg polymorphism in the IRS-1 gene and birth weight in newborn children with adequate gestational age.
Material and methods: 100 newborn children with adequate gestational age (38–42 weeks), whose mother had no disorders during pregnancy, were studied. Genomic DNA was extracted from umbilical cord blood leukocytes, and Gly972Arg polymorphism in the IRS-1 gene was genotyped using the PCR-based method.
Results: Birth weight was significantly lower in the newborn with the IRS-1 Gly972Arg polymorphism compared with a control group (3161.75 ± 380.86 g vs. 3427.92 ± 468.86 g). Body length and head circumference at birth were also lower in the neonates with that polymorphism (54.38 ± 3.13 cm vs. 52.69 ± 2.91 cm, and 34.08 ± 1.47 vs. 33.63 ± 0.81, respectively).
Conclusions: The results suggest that the Gly972Arg genotype is associated with lower birth weight, body length and head circumference in neonates with adequate gestational age.
Get Citation

Keywords

IRS-1; Gly972Arg; birth weight; type 2 diabetes

About this article
Title

The polymorphism in insulin receptor substrate-1 gene and birth weight in neonates at term

Journal

Endokrynologia Polska

Issue

Vol 59, No 3 (2008)

Pages

212-216

Published online

2008-05-08

Bibliographic record

Endokrynologia Polska 2008;59(3):212-216.

Keywords

IRS-1
Gly972Arg
birth weight
type 2 diabetes

Authors

Edyta Simońska-Cichocka
Janusz Gumprecht
Marcin Zychma
Agnieszka Witkowska
Hanna Misiołek
Helena Slawska
Anna Oslislo
Władysław Grzeszczak

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl